Current therapeutic regimens include angiotensin II receptor blocker (ARB) and inhibitors for angiotensin-converting enzyme (ACE) to reduce the high blood pressure-associated renal complications and progression to DN (3, 4). This evidence concerns the gene ACE and blood pressure trait.